Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(3 years from now) | |
US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(5 years from now) | |
US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(7 years from now) | |
US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(12 years from now) | |
US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 6, 2025 |
Orphan Drug Exclusivity (ODE) | Mar 6, 2027 |
NCE-1 date: 2024-03-06
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL
16
United States
8
Japan
7
European Union
5
Korea, Republic of
5
China
4
Spain
4
Mexico
3
Australia
3
EA
3
Israel
3
Croatia
3
Canada
3
Denmark
3
Tunisia
3
Peru
3
Cyprus
3
Singapore
3
Portugal
3
Poland
3
Slovenia
3
Hungary
3
Taiwan
3
Lithuania
2
Ecuador
2
New Zealand
2
Chile
2
Philippines
2
Morocco
2
Norway
2
Argentina
2
Brazil
2
South Africa
1
Luxembourg
1
IB
1
Netherlands
1
Malaysia
1
ME
1
Jordan
1
Ukraine
1
Russia
1
Hong Kong
1
Guatemala
1
RS
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic